Lip enhancement with hyaluronic acid–based gel was well-tolerated and associated with high satisfaction rates for natural-appearing lips lasting for 9 months, according to recent study results.
Ulf Samuelson, MD, PhD, of Akademikliniken in Stockholm, Sweden, and colleagues evaluated the safety and efﬁcacy of an injection procedure of stabilized hyaluronic acid–based, lidocaine-containing gel of nonanimal origin (Restylane Lip Volume, Q-Med AB) for the purpose of lip enhancement.
The open-label, multicenter, baseline-controlled study included 30 patients aged 18 to 60 years who underwent the lip procedure; retreatment was offered at 3 months. The researchers assessed efﬁcacy during the 9 months using the Global Aesthetic Improvement Scale, the Medicis Lip Fullness Scale and a patient questionnaire. A 14-day patient diary and recording of adverse events throughout the entire study were used to assess safety. Mean injection volume for both the upper and lower lips was 1 mL at initial treatment and 0.9 mL at retreatment.
According to study results, between 86% and 97% of patients and independent evaluators assessed the upper and lower lips as “improved” during the 9 months following treatment. Moreover, for all study visits, between 72% and 93% of patients reported satisfaction with outcomes of their lips and 96% reported natural-appearing lips.
The most common adverse events were mild-to-moderate local injection site reactions and included injection site pain in 10% of patients, implant site hematoma in 17% of patients and implant site mass in 23% of patients.
“The pursuit of fuller lips among women and men, as well as the availability of nonsurgical options to meet this desire, has increased markedly during recent years,” the researchers wrote. “Overall, most subjects were satisﬁed with treatment results based on both Global Aesthetic Improvement Scale evaluations and the subject questionnaire, regardless of if they had been retreated or if they had treatment-related adverse events.”
Disclosure: The researchers report no relevant financial disclosures.